Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1377

Sort by

Sort Order Select

Journal Articles

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Blood blood.2024023930.

https://doi.org/10.1182/blood.2024023930

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2023-178115

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Ekatherine Asatiani, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1813.

https://doi.org/10.1182/blood-2023-188051

Published: 2023

Journal Articles

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2023-182250

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG

Blood (2023) 142 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2023-178110

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

Alex Bataller, Hagop M. Kantarjian, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A Abbas, Elias Jabbour, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2023-179245

Published: 2023

Journal Articles

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Blood (2023) 142 (Supplement 1): 656.

https://doi.org/10.1182/blood-2023-178150

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Sankalp Arora, Jayastu Senapati, Naveen Pemmaraju, Prithviraj Bose, Lucia Masarova, Guillermo Montalban-Bravo, Abhishek Maiti, Tapan M. Kadia, Elias Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Naval Daver

Blood (2023) 142 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2023-187035

Published: 2023

Journal Articles

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Blood (2023) 142 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2023-187020

Published: 2023

Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2023-178035

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Samuel Urrutia, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2023-179979

Published: 2023

Journal Articles

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Wei-Ying Jen, Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Lewis Nasr, Courtney D. DiNardo, Marianne Zoghbi, Jovitta Jacob, Edith Roy, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2023-182982

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

“Dose-Dense” Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis

Trevor Jamison, Hagop M. Kantarjian, Shilpa Paul, Branko Cuglievan, David McCall, Nitin Jain, Fadi G. Haddad, Kayleigh R. Marx, Caitlin R Rausch, J. Michael Savoy, Lewis Nasr, Cedric Nasnas, Marianne Zoghbi, Rebecca Garris, Farhad Ravandi, Marina Y. Konopleva, Elias Jabbour, Nicholas J. Short

Blood (2023) 142 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2023-188530

Published: 2023

NARROW

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

“Dose-Dense” Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only